Posted by Michael Wonder on 26 Aug 2020
Metacrine announces MET409 receives FDA fast track designation for the treatment of NASH
25 August 2020 - Metacrine today announced that the U.S. FDA has granted fast track designation to MET409, the company’s lead farnesoid X receptor agonist, for the treatment of non-alcoholic steatohepatitis.
This designation was granted to MET409 based on data from a completed Phase 1b study in patients with non-alcoholic steatohepatitis as well as pre-clinical studies.
